Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biodim lets NuPharm access French market

Executive Summary

NuPharm has completed a deal to buy French firm Laboratoire Biodim from Weinberg Capital Partners’ Pharma Omnium International, for an undisclosed sum. “This strategic acquisition enables NuPharm to enter France and expand its European footprint,” the group observed, “into its fifth country after Germany, Spain, Italy and Poland.” Created in 2016, Nupharm was the result of combining five companies – Spain’s Qualigen, Laboratorios Lesvi and Inke; Germany’s Neuraxpharm, which also operates in Poland; and Italy’s FB Health – with investment group Apax Partners.

You may also be interested in...

Góra Leads Neuraxpharm’s Push Into Poland

Neuraxpharm has kicked off its operations in Poland with the appointment of Wojciech Góra as general manager of its new Neuraxpharm Polska business.

Neuraxpharm Strengthens French Business By Appointing Brun As General Manager

European CNS specialist Neuraxpharm is set to enhance its position in the French market by appointing Pierre-Hervé Brun as general manager of its French affiliate. The firm has also strengthened its international identity by rebranding its Spanish subsidiary Qualigen to Neuraxpharm Spain.

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18

Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts